生物制剂改善病情抗风湿药治疗类风湿关节炎疗效的系统文献综述:为2016年EULAR建议更新提供依据
该系统性文献综述检索了2013年1月至2016年2月发表的III/IV期(或II期)随机对照试验,评估生物制剂改善病情抗风湿药(bDMARDs)在类风湿关节炎(RA)中的疗效,为EULAR特别工作组治疗建议更新提供证据。结果显示bDMARD联合传统合成DMARD优于单用csDMARD(1A级证据),达标治疗策略有效(1B级),bDMARD失败后换用另一种bDMARD可改善临床应答(1A级),持续bDMARD治疗维持缓解最佳但减量或延长间隔可行(2B级)。
要点
- bDMARD联合csDMARD优于单用csDMARD(1A级证据)。
- 达标治疗策略下起始并升级csDMARD、无效时加用bDMARD有效(1B级)。
- bDMARD失败后换用另一种bDMARD可改善应答(1A级),减量可行(2B级)。
核心结论
- 该系统性文献综述一致证实了bDMARDs在RA中既往报告的疗效,并补充了bDMARD转换和减量的信息。
研究设计与样本
- 检索MEDLINE、EMBASE和Cochrane数据库,纳入2013年1月至2016年2月发表的III期或IV期(缺乏时II期)随机对照试验,并获取ACR和EULAR会议摘要。
主要发现
- bDMARD联合csDMARD优于单用csDMARD(1A级证据)。
- 达标治疗策略下起始并升级csDMARD、无效时加用bDMARD是有效方法(1B级)。
- bDMARD失败后换用另一种bDMARD可改善临床应答(1A级),但换用不同作用机制药物未见明确优势。
- 缓解或低疾病活动度患者持续bDMARD维持应答最佳,但减量或延长间隔可行,相当比例患者可实现无bDMARD缓解(2B级)。
- 多个新型bDMARD和bDMARD生物类似药显示疗效(1B级)。
关键数值与推荐
- bDMARD联合csDMARD优于单用csDMARD的证据等级为1A。
- 达标治疗策略(起始并升级csDMARD、无效时加用bDMARD)的证据等级为1B。
- bDMARD失败后换用另一种bDMARD改善应答的证据等级为1A。
- 持续bDMARD维持缓解最佳、减量或延长间隔可行且可实现无bDMARD缓解的证据等级为2B。
- 新型bDMARD和生物类似药疗效的证据等级为1B。
临床怎么用
- RA患者应优先考虑bDMARD联合csDMARD治疗。
- 采用达标治疗策略,csDMARD无效时加用bDMARD。
- bDMARD失败后可换用另一种bDMARD,缓解后可考虑减量或延长间隔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained. RESULTS: The RCTs confirmed greater efficacy with a bDMARD+conventional synthetic DMARD (csDMARD) versus a csDMARDs alone (level 1A evidence). Using a treat-to-target strategy approach, commencing and escalating csDMARD therapy and adding a bDMARD in cases of non-response, is an effective approach (1B). If a bDMARD had failed, improvements in clinical response were seen on switching to another bDMARD (1A), but no clear advantage was seen for switching to an agent with another mode of action. Maintenance of clinical response in patients in remission or low disease activity was best when continuing rather than stopping a bDMARD, but bDMARD dose reduction or 'spacing' was possible, with a substantial proportion of patients achieving bDMARD-free remission (2B). RCTs have also demonstrated efficacy of several new bDMARDs and biosimilar DMARDs (1B). CONCLUSIONS: This systematic literature review consistently confirmed the previously reported efficacy of bDMARDs in RA and provided additional information on bDMARD switching and dose reduction.
引用
- Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28283512. doi:10.1136/annrheumdis-2016-210713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。